Sightstream Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$2.04M
- Investors
-
3
Sightstream General Information
Description
Operator of a biotechnology research company intended to reverse ocular cell death. The company develops cytoprotectives and pro-regenerative technologies that prevent and reverse the death of cells in the ocular cell system, enabling healthcare providers to help patients prevent and recover from ocular cell damage.
Contact Information
Website
www.sightstreambio.comCorporate Office
- 266 Main Street, Building 2
- Suite 11
- Medfield, MA 02052
- United States
Corporate Office
- 266 Main Street, Building 2
- Suite 11
- Medfield, MA 02052
- United States
Sightstream Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A) | 16-Oct-2025 | $2.04M | Completed | Generating Revenue | ||
| 2. Seed Round | 03-Jun-2022 | Completed | Generating Revenue | |||
| 1. Merger/Acquisition | 25-May-2022 | Completed | Generating Revenue |
Sightstream Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-6 | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 5,952,672 | $0.000100 | 8% | $0.49 | $0.49 | 1x | $0.49 | 0% |
| Seed-1 | 1,225,989 | $0.000100 | 8% | $2.65 | $2.65 | 1x | $2.65 | 5.56% |
Sightstream Patents
Sightstream Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4565258-A2 | Compositions for the treatment of disease | Pending | 03-Aug-2022 | ||
| EP-4565258-A4 | Compositions for the treatment of disease | Pending | 03-Aug-2022 | ||
| US-20260151434-A1 | Compositions for the treatment of disease | Pending | 03-Aug-2022 | ||
| WO-2024030950-A2 | Compositions for the treatment of disease | Inactive | 03-Aug-2022 | ||
| WO-2024030950-A3 | Compositions for the treatment of disease | Inactive | 03-Aug-2022 | A61K35/30 |
Sightstream Signals
Sightstream Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 7G Bioventures | Venture Capital | Minority | ||
| Safar Partners | Venture Capital | Minority | ||
| ShangBay Capital | Venture Capital | Minority |
Sightstream FAQs
-
When was Sightstream founded?
Sightstream was founded in 2020.
-
Where is Sightstream headquartered?
Sightstream is headquartered in Medfield, MA.
-
What is the size of Sightstream?
Sightstream has 7 total employees.
-
What industry is Sightstream in?
Sightstream’s primary industry is Biotechnology.
-
Is Sightstream a private or public company?
Sightstream is a Private company.
-
What is the current valuation of Sightstream?
The current valuation of Sightstream is .
-
What is Sightstream’s current revenue?
The current revenue for Sightstream is .
-
How much funding has Sightstream raised over time?
Sightstream has raised $5.11M.
-
Who are Sightstream’s investors?
7G Bioventures, Safar Partners, and ShangBay Capital have invested in Sightstream.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process